A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
TORTORA, GIAMPAOLO;MELISI, Davide;
2005-01-01
Abstract
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
